Events

Search Language

Deutsch / German | Use language selector above (below, on mobile) to search additional languages

See by

Open filter

247 items matching filters

Search Results

Events

Nuts and Bolts of Corporate Bankruptcy 2022

Evan Hollander serves as co-chair and panelist of the Practicing Law Institute (PLI) program "Nuts and Bolts of Corporate Bankruptcy 2022.

Events

2022 P3 Government Conference

Energy & Infrastructure partner Matthew Neuringer moderated a panel on Thursday, December 1, on “IIJA and Transportation: What Have We Learned One Year Later?” during the 2022 P3 Government Conference. The panel covered the impact of the Infrastructure Investment and Jobs Act (IIJA) on ...

Events

2022 TechGC Global Summit

Thora Johnson will be leading a breakout topic session at the 2022 TechGC Global Summit.

Events

Post-Issuance Compliance Workshop

JOIN BLX AND ORRICK AT THE POST-ISSUANCE COMPLIANCE WORKSHOP A Comprehensive Overview of Post-Issuance Tax Law and SEC Secondary Market Disclosure for 501(c)(3) Organizations and State and Local Government Issuers Who Utilize Tax-Exempt Financing Virgin Hotels Nashville and Virtual - November 3-4, ...

Events

A Word About Wind’s 2022 Financing Wind North America Conference

Orrick is proud to sponsor A Word About Wind’s 2022 Financing Wind North America Conference, where Blake Winburne will moderate the “Offshore Wind: Is the Momentum now Unstoppable?” panel discussion on opportunities and challenges for the U.S. offshore wind sector and building a robust supply ...

Events

2022 NAGTRI National Anticorruption Academy

Daniel R. Alonso moderated a conversation on investigating and prosecuting high-profile cases and the need for maintaining confidentiality, fairness, and an unbiased approach throughout the process.

Events

Are there still opportunities in China and Asia for US biopharmas?

China is the second largest pharmaceutical market in the world, growing to $205bn by 2026. With an increasing focus on innovation and early access, many US biopharmas have found that an anchor in China supports accelerated clinical development and creates incremental value via either through equity ...